Todos Medical Announces August Sales of $1,190,000, Up 100% Compared with July

New York, NY – (NewMediaWire) – September 3, 2020 – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced sales for the month of August 2020 were $1,190,000. This compares with sales for the month of July 2020 of $550,000, with growth driven by week-over-week increases in demand for extraction reagents and automated extraction equipment.

During August, Todos also signed sales contracts with laboratories in New York, Texas and Wisconsin with a total value of more than $35 million and the right to supply up to 280,000 COVID-19 PCR tests per day.  Todos also entered into a common stock purchase agreement with Lincoln Park Capital, and signed an agreement with a South Korean manufacturer of rapid diagnostic tests for U.S. distribution rights to its proprietary 10-minute rapid point-of-care  (POC) antigen test (Rapid Antigen) and its proprietary 40-minute rapid POC PCR test (Rapid PCR) for SARS-CoV-2. Additionally, the Company announced positive analytical performance data for its proprietary saliva-based point of care rapid 3C protease COVID-19 test currently being developed with joint venture partner NLC Pharma.

“I’m pleased to be reporting 100% sequential-month sales growth while in parallel advancing our business strategy with new sales agreements and key strategic partnerships with global med-tech leaders, making several executive appointments and strengthening our balance sheet,” said Gerald E. Commissiong, President & CEO of Todos. “We believe there is opportunity for Todos to add significant innovation for cancer and Alzheimer’s testing in the U.S. healthcare system, and we intend to vigorously pursue these opportunities while continuing to drive sales growth for our COVID-19 testing business. As we expand our sales reach, we have initiated clinical studies for proprietary saliva-based 3C Protease and entered into a partnership with Pangea to integrate testing data reporting functions into telehealth platforms to improve data reporting functions for the ‘bubbles’ we are looking to help our clients establish across the United States. Taken together, we believe taking a more comprehensive approach to COVID-19 is required, as end clients are looking to purchase integrated solutions that can facilitate re-opening safely.”

For information related to Todos Medical’s COVID-19 testing capabilities, please visit www.todoscovid.com

For testing and PPE inquiries, please email sales@todosmedical.com.

About Todos Medical Ltd.

Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the third quarter of 2020.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain. In July 2020, Todos completed the acquired Breakthrough Diagnostics, Inc., the owner of the LymPro Test intellectual property, from Amarantus Bioscience Holdings, Inc. (OTC: AMBS).

Additionally, Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos has formed strategic partnerships with Meridian Health, Moto-Para Foundation to deploy COVID-19 testing in the United States.

For more information, please visit https://www.todosmedical.com/.

Forward-looking Statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Investor Contact:

Kim Sutton Golodetz

LHA Investor Relations

Senior Vice President

(212) 838-3777

kgolodetz@lhai.com

Corporate Contact:

Priyanka Misra

Todos Medical

(917) 882-3733

Priyanka@todosmedical.com